logo
Plus   Neg
Share
Email

Astellas Pharma Gets Positive CHMP Opinion For XOSPATA

Astellas Pharma Inc. said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion recommending the oral once-daily therapy XOSPATA or gilteritinib as a monotherapy for the treatment of adult patients who have relapsed or refractory (resistant to treatment) acute myeloid leukemia or AML with a FLT3 mutation (FLT3mut+).

If approved by the European Commission, gilteritinib has the potential to improve treatment outcomes for AML patients with the most common mutations - FLT3 internal tandem duplication (ITD) and FLT3 tyrosine kinase domain (TKD) - and would be one of the few advances for the treatment of AML in Europe over the past 40 years.

Gilteritinib received accelerated assessment from the EMA, which allowed the CHMP to reduce the timeframe for approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Daimler AG, the maker of Mercedes-Benz cars, said Thursday that it has agreed to pay more than $2.2 billion to settle U.S. claims over emissions from its diesel vehicles. A new class-action lawsuit filed against Facebook accuses the company's photo and video-sharing app Instagram of illegally collecting biometric data of as many as 100 million users without their consent, according to reports. The lawsuit filed in a state court in California, alleges that Instagram uses its photo-tagging technology to create a database of users' facial features. Stein Mart, Inc. has joined the ever growing list of U.S. retailers who filed for bankruptcy protection amid the ongoing coronavirus (COVID-19) pandemic. The beleaguered off-price retailer filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Middle District of Florida.
RELATED NEWS
Follow RTT